

I. Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims

Claim 1 (currently amended): A composition for the percutaneous administration of an opioid analgesic which comprises a therapeutic amount of the opioid analgesic in association with a vehicle for providing a transdermal flux of the opioid analgesic when applied to a human body surface or membrane and a quantity of a distressing substance selected from the group consisting of emetics, nauseants, flavouring substances, ergolides, bitter quaternary ammonium compounds, atropine or salts thereof, and mixtures thereof,

wherein said composition is free of a non-permeant opioid antagonist, and said distressing substance does not penetrate the skin of a human patient when the composition is applied to the skin of said patient and is included in an effective amount and such that a distressful reaction is produced when the composition is ingested orally or is administered as a parenteral bolus injection.

Claim 2 (currently amended): A composition for the percutaneous administration of an opioid analgesic which comprises a therapeutic amount of the opioid analgesic in association with a vehicle for providing a transdermal flux of the opioid analgesic when applied to a human body surface or membrane, a quantity of a distressing substance, and a membrane which is permeable to the opioid analgesic and non-permeable to the distressing substance, said distressing substance selected from the group consisting of emetics, nauseants, flavouring substances, ergolides, bitter quaternary ammonium compounds, atropine or salts thereof, and mixtures thereof, said composition is free of a non-permeant opioid antagonist, and said distressing substance not penetrating the skin of a human patient when the composition is applied to the skin of said patient and is included in an effective amount and such that a distressful reaction is produced in said patient when the composition is ingested orally or is administered as parenteral bolus injection.

Claims 3-4 (cancelled)

Claim 5 (previously presented): A composition according to claim 1, wherein the distressing substance is incorporated in a vehicle being the same vehicle as for the opioid analgesic.

Claim 6 (original): A composition according to claim 5, wherein the vehicle includes a penetration enhancer.

Claim 7 (previously presented): A composition according to claim 1, wherein the opioid analgesic is selected from the group consisting of morphine, hydromorphone, buprenorphine, ketamine, fentanyl, tramadol, or pharmaceutically acceptable and percutaneously transmissible salts thereof.

Claim 8 (previously presented): A composition according to claim 1 wherein the opioid analgesic is a narcotic opioid analgesic.

Claim 9 (previously presented): A composition according to claim 1, wherein the opioid analgesic is in an aqueous and/or alcoholic solution, or incorporated in a matrix including a pressure sensitive adhesive.

Claim 10 (previously presented): A transdermal device containing a composition according to claim 1.

Claim 11 (original): A device according to claim 10, which is an adhesive matrix patch and comprises an impermeable backing layer, a matrix layer which contains the opioid analgesic and a penetration enhancer and distressing substance.

Claim 12 (original): A device according to claim 10, which is a reservoir device.

Claim 13 (previously presented): A device according to claim 10, which is a monolithic patch.

Claim 14 (previously presented): A composition according to claim 1, which contains buprenorphine or pharmaceutically acceptable salt thereof as the opioid analgesic and atropine or pharmaceutically acceptable salt thereof, or an ergolide or pharmaceutically acceptable salt thereof as the distressing substance.

Claim 15 (previously presented): A device according to claim 10, which contains buprenorphine or pharmaceutically acceptable salt thereof as the opioid analgesic and atropine or pharmaceutically acceptable salt thereof, or an ergolide or pharmaceutically acceptable salt thereof as the distressing substance.

Claim 16 (previously presented): A composition according to claim 2, wherein the distressing substance is incorporated in a vehicle being the same vehicle as for the opioid analgesic.

Claim 17 (currently amended): A composition for the percutaneous administration of an opioid analgesic which comprises a therapeutic amount of the opioid analgesic in association with a vehicle for providing a transdermal flux of the opioid analgesic when applied to a human body surface or membrane, and a quantity of a distressing substance selected from the group consisting of ergolides, bitter quaternary ammonium compounds, atropine or salts thereof, and mixtures thereof, said composition is free of a non-permeant opioid antagonist, and said distressing substance separated from the opioid analgesic, not penetrating the skin of a human patient when the composition is applied to the skin of said patient and is included in an effective amount and such that a distressful reaction is produced when the composition is ingested orally or is administered as a parenteral bolus.

Claim 18 (currently amended): A composition for the percutaneous administration of an opioid analgesic which comprises a therapeutic amount of the opioid analgesic in

association with a vehicle for providing a transdermal flux of the opioid analgesic when applied to a human body surface or membrane and a quantity of a distressing substance selected from the group consisting of the emetic ipecacuanha or derivatives thereof, nauseants, flavouring substances, the quaternary ammonium compound denatonium benzoate, the ergolides bromocriptin, lisoline, pergolide and lysuride or salts thereof, atropine or salts thereof, and mixtures thereof, wherein said composition is free of a non-permeant opioid antagonist, and said distressing substance is non permeant through human skin and is included in an effective amount and such that a distressful reaction is produced when the composition is ingested orally or is administered as a parenteral bolus injection.

Claim 19 (Currently amended): A composition according to claim 18, wherein the distressing substance is selected from the group consisting of atropine or a salt thereof, an ergolide or a pharmaceutically acceptable salt thereof, and ipecacuanha.

Claim 20 (new): The composition of claim 1, wherein the distressful reaction is a reaction selected from the group consisting of vomiting, nausea and a severe headache.

Claim 21 (new): The composition of claim 2, wherein the distressful reaction is a reaction selected from the group consisting of vomiting, nausea and a severe headache.

Claim 22 (new): The composition of claim 17, wherein the distressful reaction is a reaction selected from the group consisting of vomiting, nausea and a severe headache.

Claim 23 (new): The composition of claim 18, wherein the distressful is a reaction selected from the group consisting of vomiting, nausea and a severe headache.